These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36880666)

  • 1. A multiple-step screening protocol to identify norepinephrine and dopamine reuptake inhibitors for depression.
    Wang P; Yan F; Dong J; Wang S; Shi Y; Zhu M; Zuo Y; Ma H; Xue R; Zhai D; Song X
    Phys Chem Chem Phys; 2023 Mar; 25(12):8341-8354. PubMed ID: 36880666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD.
    Wang P; Fu T; Zhang X; Yang F; Zheng G; Xue W; Chen Y; Yao X; Zhu F
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2766-2777. PubMed ID: 28757337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative modeling of the human monoamine transporters: similarities in substrate binding.
    Koldsø H; Christiansen AB; Sinning S; Schiøtt B
    ACS Chem Neurosci; 2013 Feb; 4(2):295-309. PubMed ID: 23421681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
    Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
    J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Swanson TL; Nilsen A; Janowsky A
    Psychopharmacology (Berl); 2019 Mar; 236(3):939-952. PubMed ID: 30397775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation.
    Yatin SM; Miller GM; Madras BK
    J Neurosci Methods; 2005 Apr; 143(1):69-78. PubMed ID: 15763138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
    Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J
    PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters.
    Severinsen K; Kraft JF; Koldsø H; Vinberg KA; Rothman RB; Partilla JS; Wiborg O; Blough B; Schiøtt B; Sinning S
    ACS Chem Neurosci; 2012 Sep; 3(9):693-705. PubMed ID: 23019496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release.
    Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Swanson T; Johnson RA; Janowsky A
    J Pharmacol Exp Ther; 2017 Jan; 360(1):33-47. PubMed ID: 27799294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling the structural determinants of aminoketone derivatives as hNET and hDAT reuptake inhibitors by field-based QSAR based on molecular docking.
    Wang P; Jing C; Yu P; Lu M; Xu X; Pei Q; Yan F
    Technol Health Care; 2021; 29(S1):257-273. PubMed ID: 33682763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
    Zhang P; Terefenko EA; Bray J; Deecher D; Fensome A; Harrison J; Kim C; Koury E; Mark L; McComas CC; Mugford CA; Trybulski EJ; Vu AT; Whiteside GT; Mahaney PE
    J Med Chem; 2009 Sep; 52(18):5703-11. PubMed ID: 19722525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.
    Xue W; Wang P; Tu G; Yang F; Zheng G; Li X; Li X; Chen Y; Yao X; Zhu F
    Phys Chem Chem Phys; 2018 Feb; 20(9):6606-6616. PubMed ID: 29451287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation.
    Xue W; Yang F; Wang P; Zheng G; Chen Y; Yao X; Zhu F
    ACS Chem Neurosci; 2018 May; 9(5):1128-1140. PubMed ID: 29300091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
    Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
    Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.
    Guptaroy B; Fraser R; Desai A; Zhang M; Gnegy ME
    Mol Pharmacol; 2011 Mar; 79(3):520-32. PubMed ID: 21149640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
    Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
    Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted methcathinones differ in transporter and receptor interactions.
    Eshleman AJ; Wolfrum KM; Hatfield MG; Johnson RA; Murphy KV; Janowsky A
    Biochem Pharmacol; 2013 Jun; 85(12):1803-15. PubMed ID: 23583454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
    Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
    Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do 2-(Benzoyl)piperidines Represent a Novel Class of hDAT Reuptake Inhibitors?
    Jones CB; Eltit JM; Dukat M
    ACS Chem Neurosci; 2023 Feb; 14(4):741-748. PubMed ID: 36745029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of an endogenous zinc-binding site in the human dopamine transporter.
    Norregaard L; Frederiksen D; Nielsen EO; Gether U
    EMBO J; 1998 Aug; 17(15):4266-73. PubMed ID: 9687495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.